Shanghai, China – 6 June, 2014 – MicroPort Medical (Group) Co ("MicroPort") recently attended the 8th Oriental Congress Cardiology to further promote its revolutionary product Firehawk.
During the event held from 28 May to 31 May, MicroPort presented Firehawk's safety and efficiency through relaying operations conducted by Shanghai's Ruijin Hospital and Renji Hospital, in which a total of 18 Firehawk stents were successfully implanted.
Meanwhile, several renowned experts were invited to share MicroPort's latest research results in regard of Firehawk, the Target Eluting System, in the event. Bo Xu, Director of Intervention Catheter Department with Fuwai Hospital, delivered a speech on "Firehawk's latest clinical outcome and special features." He noted that the incident rate of thrombosis for Firehawk stent has so far remained zero according to three-year follow-up results of Target clinical trials.
"I'm so proud to see China has such a globalized company (like MicroPort) and we Chinese can design, produce and manufacture such a global leading product like Firehawk stent," said Professor Shubin Qiao of Fuwai Hospital. "I'm looking forward to seeing Firehawk promoted across China and the whole world."
Privacy settings
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.
For more information, please see our Cookie Policy.